Biopharmaceutical Third Party Logistics (3PL) Market Growth, Demand and Challenges of the Key Industry Players 2024-2032
                     Global Biopharmaceutical 
Third Party Logistics (3PL) 
Market Research and 
Forecast Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
Accord ing  to  the  la tes t  repor t  by  IMARC Group ,  t i t led  "Biopharmaceut ica l  
Thi rd  Par ty  Logis t ics  (3PL)  Market :  Globa l  Industry  Trends,  Share ,  S ize ,  
Growth,  Oppor tuni ty  and Forecast  2024-2032 ,"  the  g loba l  b iopharmaceu t i ca l  
th i rd  pa r ty  log is t i cs  (3PL)  marke t  s ize  reached  US$ 123 .0  B i l l ion  in  2023 .
Report Biopharmaceu t i ca l  t h i rd -pa r t y  log is t i cs  (3PL)  re fe rs  to  the  se rv ices  wh ich  a re  
ou tsourced  by  pha rmaceu t i ca l  compan ies  th rough  th i rd -par t y  o rgan iza t ions .  I t s  
Highlight and serv ices  inc lude  rece iv ing  sma l l  mo lecu le  d rugs ,  vacc ines ,  b io log ics ,  and  o the r  med ica l  p roduc ts ,  fu l f i l l i ng  o rders ,  and  hand l ing  inven to ry  o f  the  goods .  
In  recen t  years ,  3PL  has  ga ined  momentum,  as  i t  he lps  pharmaceu t i ca l  and  
Description med ica l  t he rap ies ,  m in im iz ing  med ic ine  cos ts  by  reduc ing  was te fu l  ove rhead  
expenses ,  enhanc ing  t ranspor ta t ion  se rv ices ,  ensur ing  un in te r rup ted  p roduct  
supp ly ,  and  imp rov ing  the  overa l l  e f f i c ienc ies  o f  t he  ins t i tu t ion .
Request  for  a  PDF sample  o f  th is  repor t :  
h t tps : / /www. imarcgroup .com/b iopharmaceu t ica l - th i rd -pa r t y - log is t i cs -marke t / req
ues tsamp le
Report Description
Gl o b a l  B i o p h a r m a c e u t ic a l  T h i r d  P a r t y  L o g i s t i cs  ( 3P L )  Ma r k e t  T r e n d s :
On e  o f  t he  p r i m a ry  f ac t o r s  d r i v i n g  t h e  m a r ke t  i s  t h e  e x p o ne n t i a l  g r o w t h  i n  t h e  p h a r ma c e u t i ca l  i n d u s t r y .  A d d i t i o na l l y ,  t h e  
g r o w i n g  t r e nd  o f  ou t s o u r c i n g  l o g i s t i c s  b y  n um e r o u s  m e d i c a l  o r g a n i z a t i o n s  t o  o p t i m i z e  t h e i r  d i s t r i b u t i o n  n e t w o r k  i s  c r e a t i n g  a  
po s i t i v e  ma r k e t  o u t l oo k .  O th e r  t h an  t h i s ,  t h e  d e ma n d  f o r  3 P L  h as  e x p o ne n t i a l l y  r i s e n  o n  ac c o u n t  o f  t h e  s u d d e n  o u t b r ea k  o f  
t he  c o ro n a v i r us  d i s e as e  ( C O V I D - 1 9 )  t o  r e d uc e  t he  d r u g  s u p p l y  d i s r u p t i o n s  a n d  e ns u r e  t h e  a va i l a b i l i t y  o f  c r i t i ca l  c a re  d r u gs .  
B e s i d e s  t h i s ,  n u me r o u s  t e ch n o l o g i ca l  i n n ov a t i o ns ,  s u ch  as  t he  i n t ro d u c t i on  o f  m ob i l e  c l o u d  c o mp u t i n g ,  w a r e h ou s e  r o b o t i c s ,  
r e a l - t i me  m o n i to r i n g ,  an d  d a ta  m i n i n g  s o l u t i o ns ,  a r e  po s i t i v e l y  i n f l u e n c i ng  t h e  m a rk e t  g r ow t h .  T h e  n e w l y  i n t r o d uc e d  
t ec h n o l o g i e s  a s s i s t  i n  a u to m a t i ng  l og i s t i c s - r e l a t ed  p r oc e d u re s  a n d  re d u c i n g  op e r a t i on  c o m p l e x i t i e s ,  hu m a n  e r r o r s ,  a n d  
da m a g es  t h a t  a r e  ca u s e d  to  t h e  p r o d u c t s  i n  t r an s i t .  Mo r e o ve r ,  t he  i n t e r n e t  o f  t h i n g s  ( I o T )  a nd  n e a r  f i e l d  c o mm u n i c a t i o n  ( N F C )  
ba s e d  c o l d  c h a i n  m o n i t o r i n g  p r o du c t s  a r e  u s ed  t o  ma n a ge  t e m p e r a t u re - s e n s i t i v e  p h a rm a c eu t i c a l s  a n d  a ch i e v e  r e a l - t i m e  
up d a t e s  a n d  a l e r t s  r e g a r d i n g  t h e  s h i p me n t .
L o o k i n g  f o r w ar d ,  I MA R C  G r o u p  e x p ec t s  th e  m a r k e t  v a l u e  t o  r ea c h  U S $  19 5 . 4  B i l l i o n  b y  2 0 3 2 ,  e x p a n d i n g  a t  a  C A G R  o f  
5 . 2 %  d u r i n g  t h e  fo r e c a s t  p e r io d  ( 20 2 4 - 2 03 2 ) .
V i e w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w ww . i m a r c g ro u p . co m / b i o p h a r m a c e u t i c a l - th i r d - p a r t y - l o g i s t i c s - m a r k e t
Breakup by Supply Chain:
• Cold Chain
• Non-Cold Chain
 
Breakup by Service Type:
Report • Transportation
o Air Freight
Segmentation
o Sea Freight
o Overland
• Warehousing and Storage
• Others
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Latin America
Report 
• Middle East and Afr ica
Segmentation
• Agi l i ty Logist ics
• AmerisourceBergen Corporation
• DB Schenker (Deutsche Bahn)
Competitive • DHL International  GmbH (Deutsche Post)
• FedEx Corporation
Landscape 
• Kerry Logist ics Network Limited
with Key • Kuehne + Nagel International  AG
Players • McKesson Corporation
• SF Express Co. Ltd.
• United Parcel  Service of America Inc.
What is the global biopharmaceutical third party 
logistics (3PL) market growth?
What are the global biopharmaceutical third party 
logistics (3PL) market drivers?
What are the key industry trends in the global 
Key biopharmaceutical third party logistics (3PL) market?
Questions What is the impact of COVID-19 on the global 
biopharmaceutical third party logistics (3PL) market?
Answered in 
What is the global biopharmaceutical third party 
the Report logistics (3PL) market breakup by supply chain?
What is the global biopharmaceutical third party 
logistics (3PL) market breakup by service type?
What are the major regions in the global 
biopharmaceutical third party logistics (3PL) market?
Who are the key companies/players in the global 
biopharmaceutical third party logistics (3PL) market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  B i o p h a r m a c e u t i c a l  T h i r d  P a r t y  L o g i s t i c s  ( 3 P L )  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  S u p p l y  C h a i n
    6 . 1     C o l d  C h a i n
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     N o n - C o l d  C h a i n
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  S e r v i c e  T y p e
    7 . 1     T r a n s p o r t a t i o n         
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  K e y  T y p e s
       
           7 . 1 . 2 . 1  A i r  F r e i g h t
           7 . 1 . 2 . 2  S e a  F r e i g h t
           7 . 1 . 2 . 3  O v e r l a n d
        7 . 1 . 3  M a r k e t  F o r e c a s t     
    7 . 2     W a r e h o u s i n g  a n d  S t o r a g e
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3     O t h e r s
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  R e g i o n
Table of     8 . 1     N o r t h  A m e r i c a
        8 . 1 . 1  U n i t e d  S t a t e s
           8 . 1 . 1 . 1  M a r k e t  T r e n d s
Contents            8 . 1 . 1 . 2  M a r k e t  F o r e c a s t        8 . 1 . 2  C a n a d a
           8 . 1 . 2 . 1  M a r k e t  T r e n d s
           8 . 1 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 2     A s i a - P a c i f i c
        8 . 2 . 1  C h i n a
           8 . 2 . 1 . 1  M a r k e t  T r e n d s
           8 . 2 . 1 . 2  M a r k e t  F o r e c a s t
        8 . 2 . 2  J a p a n
           8 . 2 . 2 . 1  M a r k e t  T r e n d s
           8 . 2 . 2 . 2  M a r k e t  F o r e c a s t
        8 . 2 . 3  I n d i a
           8 . 2 . 3 . 1  M a r k e t  T r e n d s
           8 . 2 . 3 . 2  M a r k e t  F o r e c a s t     
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m /b i op ha rm a c eut i c a l - th i rd -pa r ty - l
o g i s t i c s -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: